Abstract 5307: Analysis of volatile organic compounds for the diagnosis of lung cancer

Abstract Background: Lung cancer is the leading cause of cancer-related deaths in the world. The prognosis of lung cancer depends on disease detection at an early stage. Recently, effectiveness of lung cancer screening by using low dose computed tomography scanning have been showing. However, it still has problems such as cost of screening and radiation exposure. Thus, less invasive and cost beneficial lung cancer screening procedure would be needed. In this context, several study to understand the efficacy of molecules from expiration of patients as a lung cancer screening were showing, but it was still controversial. In this study, we investigated to determine whether volatile organic compounds (VOC) from patients could be used for the detection for lung cancer by using novel small and unique absorbent material named MonoTrap . Method: The subjects’ gas was collected from skin and exhaled breath in a MonoTrap (GL sciences), and the VOCs were analyzed by gas chromatography/ mass spectrometry (GC/MS). First of all, we preliminary analyzed for both sample from skin and exhaled breath for 12 patients and 11 healthy volunteers to clarify which samples were more sensitive to diagnose lung cancer. Subsequently, each VOC was determined in detail for 7 healthy individuals and 4 lung cancer patients and these values were statistically analyzed. Results: By preliminary study, characteristics of VOC derived from skin were significantly correlated with cancer condition as compared with healthy volunteer by using comprehensive multivariate analysis. Therefore, we performed further quantitative analysis by targeting unique individual molecules derived from skin. In VOCs from skin, Mann-Whitney U test showed that 4-hydroxy-4-methyl-2-pentanone, hexadecane, and acetamide were significantly higher in lung cancer patients (p=0.036, p=0.006, p=0.036, respectively). Conclusion: In this study, we found that 3 kinds of VOCs could be a potential diagnostic biomarkers of lung cancer. Further prospective study is now planning to validate these data using large number samples. Citation Format: Takuya Inoue, Hironori Takagi, Yuki Owada, Yuzuru Watanabe, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Takeda Manami, Atsushi Sato, Hiroyuki Suzuki. Analysis of volatile organic compounds for the diagnosis of lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5307. doi:10.1158/1538-7445.AM2017-5307